The stock, currently trading at ₹293.95 with a market capitalisation of ₹462.98 crores, has experienced a dramatic 14.04% surge following the results announcement. This sharp rally comes after a prolonged period of weakness, with the stock still down 49.75% over the past year and trading 54.97% below its 52-week high of ₹652.75. The company's performance presents a mixed picture of operational recovery tempered by persistent margin pressures and quality concerns.
The agrochemicals sector has witnessed significant volatility over the past year, with pricing pressures and inventory corrections affecting most players. Shivalik Rasayan's Q4 FY26 performance reflects both the challenges and opportunities within this dynamic landscape, as the company navigates between volume growth and margin preservation.
Financial Performance: Strong Topline Recovery, Margin Pressure Persists
Shivalik Rasayan's Q4 FY26 revenue performance stands out as a clear highlight, with net sales reaching a quarterly high of ₹102.82 crores. The 25.33% quarter-on-quarter growth from ₹82.04 crores demonstrates strong sequential momentum, whilst the 48.18% year-on-year expansion from ₹69.39 crores signals robust market demand recovery. This topline strength pushed full-year FY26 sales to approximately ₹368 crores, representing healthy growth over the FY25 figure of ₹311 crores.
However, profitability metrics reveal a more nuanced story. The operating profit (PBDIT excluding other income) for Q4 FY26 stood at ₹12.43 crores with a margin of 12.09%, marginally down from 12.58% in the previous quarter. More concerning is the comparison with historical performance—the company achieved operating margins of 15.61% and 14.26% in Q2 and Q3 FY25 respectively, indicating persistent margin compression despite volume growth. The PAT margin of 6.97% in Q4 FY26, whilst improved from Q3's 4.47%, remains significantly below the 8.14% achieved in Q2 FY25.
| Metric | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 |
|---|---|---|---|---|---|
| Net Sales (₹ Cr) | 102.82 | 82.04 | 93.84 | 89.31 | 69.39 |
| QoQ Growth | +25.33% | -12.57% | +5.07% | +28.71% | — |
| YoY Growth | +48.18% | -3.83% | +13.83% | — | — |
| Operating Profit (₹ Cr) | 12.43 | 10.32 | 12.03 | 10.99 | 5.75 |
| Operating Margin (%) | 12.09% | 12.58% | 12.82% | 12.31% | 8.29% |
| Consolidated PAT (₹ Cr) | 4.53 | 2.70 | 3.05 | 1.60 | 4.13 |
| PAT Margin (%) | 6.97% | 4.47% | 4.58% | 3.16% | 7.48% |
The cost structure analysis reveals several pressure points. Employee costs have risen steadily to ₹15.64 crores in Q4 FY26 from ₹14.01 crores in Q1 FY26, reflecting a 11.63% increase over three quarters. Interest expenses remained elevated at ₹2.46 crores, whilst depreciation charges of ₹4.16 crores continue to weigh on profitability. The tax rate of 7.12% in Q4 FY26 appears unusually low compared to the 32.05% in Q1 FY26, suggesting potential one-time adjustments or carry-forward benefits.
Operational Challenges: Weak Capital Efficiency Undermines Growth Story
Beneath the surface of revenue growth lies a troubling pattern of deteriorating capital efficiency. The company's latest return on equity (ROE) stands at a meagre 2.40%, significantly below the average of 6.12% and far removed from industry standards. This weak ROE signals that Shivalik Rasayan is struggling to generate adequate returns on shareholder capital, raising questions about the sustainability of its business model and management's capital allocation decisions.
The return on capital employed (ROCE) paints an equally concerning picture at just 3.89% for the latest period, well below the five-year average of 9.45%. This metric, which measures how efficiently the company utilises all capital (both equity and debt) to generate operating profits, has been on a declining trajectory. The half-yearly ROCE of 4.36% represents the lowest level in recent quarters, suggesting that despite increased sales, the company is deploying capital inefficiently.
⚠️ Critical Efficiency Concerns
Return on Equity: At 2.40%, Shivalik Rasayan's ROE is exceptionally weak, indicating poor capital efficiency. This low return means shareholders are receiving minimal value for their invested capital, a significant red flag for long-term investors.
ROCE Deterioration: The latest ROCE of 3.89% and half-yearly ROCE of 4.36% represent multi-quarter lows, suggesting that increased capital deployment is not translating into proportionate profit generation.
Operating Profit Growth: Five-year EBIT growth of -1.67% annually indicates the company has been unable to grow its core operating profitability over the medium term, despite topline expansion.
The balance sheet reveals substantial capital intensity. Fixed assets stood at ₹336.64 crores as of March 2025, up significantly from ₹214.01 crores in the previous year, indicating major capital expenditure. Whilst this investment may support future growth, the immediate impact has been a drag on returns. Current assets of ₹314.64 crores and current liabilities of ₹178.20 crores suggest adequate working capital management, though the sales-to-capital-employed ratio of 0.62x remains modest.
The company's debt profile shows long-term debt of ₹13.72 crores and interest costs of approximately ₹10 crores annually, resulting in a debt-to-EBITDA ratio of 1.54x—manageable but requiring careful monitoring. The EBIT-to-interest coverage ratio of 6.08x provides some comfort, indicating the company can service its debt obligations from operating profits, albeit with limited headroom.
Agrochemical Sector Dynamics: Navigating Industry Headwinds
The pesticides and agrochemicals sector has faced significant challenges over the past 18 months, with global oversupply conditions and channel destocking pressuring both volumes and realisations. Shivalik Rasayan, as a manufacturer of organophosphate insecticides including dimethoate technical and malathion technical, operates in a segment that has witnessed intense competition from Chinese manufacturers and pricing volatility.
The company's 48.18% year-on-year revenue growth in Q4 FY26 significantly outpaces the sector's one-year return of 6.16%, suggesting either market share gains or favourable product mix shifts. However, this outperformance must be viewed against the backdrop of a weak base in Q4 FY25, when operating margins had compressed to just 8.29%. The sector-wide recovery in agrochemical demand during the second half of FY26, driven by improved monsoon patterns and channel inventory normalisation, has benefitted most players, though margin recovery remains uneven across the industry.
Industry Context: Agrochemical Recovery Underway
The Indian agrochemical sector is witnessing a gradual recovery after a challenging FY25. Improved monsoon distribution, government support for agricultural inputs, and channel inventory correction have created a more favourable demand environment. However, margin pressures persist due to elevated raw material costs and competitive intensity. Companies with strong product portfolios and operational efficiency are better positioned to capitalise on the recovery.
Shivalik Rasayan's acquisition of 44.12% equity in Medicamen Biotech Limited in 2016 was intended to diversify its product portfolio and enhance market reach. The consolidated results reflect this broader business mix, though the contribution and profitability of this subsidiary remain opaque in the available financial data. The company's manufacturing facility in Dehradun, Uttarakhand, provides access to key raw materials and benefits from state-level incentives, though infrastructure and logistics challenges in the region can impact operational efficiency.
Peer Comparison: Valuation Discount Reflects Quality Concerns
Shivalik Rasayan's positioning within the pesticides and agrochemicals peer group reveals why the market has assigned a valuation discount despite recent operational improvements. With a price-to-earnings ratio of 34.21x, the company trades at a premium to several peers, yet its price-to-book value of 0.69x sits well below the peer average of approximately 1.90x, reflecting market scepticism about the quality of its asset base and return generation capability.
| Company | P/E (TTM) | P/BV | ROE (%) | Debt/Equity | Div Yield (%) |
|---|---|---|---|---|---|
| Shivalik Rasayan | 34.21 | 0.69 | 6.12% | 0.09 | 0.19% |
| Punjab Chemicals | 18.74 | 2.90 | 20.38% | 0.33 | 0.30% |
| Dharmaj Crop | 17.61 | 2.44 | 11.64% | 0.28 | — |
| Heranba Industries | NA (Loss Making) | 0.93 | 4.37% | 0.56 | 0.51% |
| Advance Agrolife | 18.97 | 2.16 | — | 0.00 | — |
| Best Agrolife | 71.93 | 0.83 | 25.19% | 0.48 | 1.04% |
The comparison becomes stark when examining return on equity. Whilst Punjab Chemicals delivers an impressive 20.38% ROE and Best Agrolife achieves 25.19%, Shivalik Rasayan's 6.12% average ROE lags significantly. This underperformance in capital efficiency explains the market's reluctance to assign a higher P/BV multiple despite the company's lower P/E ratio. Investors are essentially pricing in concerns about the quality and sustainability of earnings.
Shivalik Rasayan does maintain a competitive advantage in leverage, with a debt-to-equity ratio of just 0.09, amongst the lowest in the peer group. This conservative capital structure provides financial flexibility and reduces downside risk during industry downturns. However, the company's minimal dividend yield of 0.19% and payout ratio of just 6.12% suggest management is retaining most earnings, presumably for growth investments—yet the weak ROCE raises questions about whether this capital reinvestment is creating shareholder value.
Valuation Analysis: Attractive Price, but Quality Concerns Persist
At the current market price of ₹293.95, Shivalik Rasayan trades at a P/E ratio of 34.21x based on trailing twelve-month earnings, moderately below the industry average P/E of 43x. The company's valuation grade of "Attractive" reflects this relative discount, though investors must weigh this against the fundamental quality concerns that justify the lower multiple.
The price-to-book value of 0.69x stands out as particularly low, suggesting the market values the company's net assets at just 69% of their book value. This discount can be interpreted in two ways: either the assets are overvalued on the balance sheet and unlikely to generate adequate returns, or the stock presents a deep value opportunity if management can improve capital efficiency. Given the weak ROE and ROCE metrics, the former interpretation appears more credible at present.
The EV/EBITDA multiple of 10.05x and EV/Sales ratio of 1.25x appear reasonable for a company with mid-teens revenue growth, though the EV/EBIT ratio of 17.03x highlights the margin compression issues that inflate this metric. The stock's valuation history shows it was upgraded to "Attractive" from "Very Attractive" in November 2025, following a period of sharp price decline that took valuations to extremely depressed levels.
From a technical standpoint, the stock's 54.97% decline from its 52-week high of ₹652.75 to the current price of ₹293.95 reflects severe loss of investor confidence. The recent 14.04% surge on results day suggests some speculative interest, but the stock remains in a bearish technical trend and trades below all major moving averages except the 5-day, 20-day, and 50-day marks. The high beta of 1.36 indicates the stock is significantly more volatile than the broader market, amplifying both upside and downside moves.
Shareholding Pattern: Stable Promoter Base, Minimal Institutional Interest
Shivalik Rasayan's shareholding structure reveals a stable promoter base but concerning lack of institutional validation. Promoter holding has remained constant at 47.37% over the past five quarters, with no pledging of shares—a positive indicator of promoter confidence and financial stability. The primary promoter entity, Growel Remedies Limited, maintains this entire stake, providing clear control and alignment with minority shareholders.
| Shareholder Category | Mar'26 | Dec'25 | Sep'25 | Jun'25 | QoQ Change |
|---|---|---|---|---|---|
| Promoter Holding | 47.37% | 47.37% | 47.37% | 47.37% | 0.00% |
| FII Holding | 4.20% | 3.89% | 4.38% | 4.36% | +0.31% |
| Mutual Fund Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Insurance Holdings | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other DII Holdings | 0.00% | 0.12% | 0.48% | 0.56% | -0.12% |
| Non-Institutional | 48.42% | 48.61% | 47.77% | 47.71% | -0.19% |
However, the institutional shareholding pattern raises red flags. Foreign institutional investors (FIIs) hold just 4.20% as of March 2026, with minimal quarter-on-quarter changes suggesting neither strong accumulation nor distribution. More concerning is the complete absence of mutual fund holdings at 0.00%, indicating that no domestic institutional fund managers see sufficient merit in the stock to establish positions. This lack of institutional sponsorship typically reflects concerns about corporate governance, business quality, or growth visibility.
The gradual decline in other domestic institutional investor (DII) holdings from 0.64% in March 2025 to effectively zero by March 2026 suggests institutions that did hold positions have been exiting. With 48.42% held by non-institutional investors (primarily retail shareholders), the stock exhibits characteristics of a promoter-retail dominated holding pattern, which can lead to higher volatility and limited liquidity during market stress.
Stock Performance: Severe Underperformance Across All Timeframes
Shivalik Rasayan's stock price performance over the past year paints a picture of severe wealth destruction for shareholders. The stock has plummeted 49.75% over the past twelve months, massively underperforming the Sensex's decline of 6.94% by a staggering 42.81 percentage points. This dramatic underperformance extends across virtually all timeframes, with the stock generating negative alpha (excess returns versus the benchmark) in nearly every period examined.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | +13.93% | +0.74% | +13.19% |
| 1 Month | +10.76% | -1.97% | +12.73% |
| 3 Months | +2.42% | -6.54% | +8.96% |
| 6 Months | -27.25% | -11.36% | -15.89% |
| Year to Date | -17.39% | -10.85% | -6.54% |
| 1 Year | -49.75% | -6.94% | -42.81% |
| 2 Years | -52.30% | +1.97% | -54.27% |
| 3 Years | -61.52% | +20.88% | -82.40% |
The recent one-week and one-month performance shows positive alpha of 13.19% and 12.73% respectively, driven primarily by the results-day surge. However, this short-term bounce does little to offset the systematic underperformance over medium to long-term horizons. The six-month return of -27.25% versus Sensex's -11.36% demonstrates that the stock has been in a sustained downtrend, underperforming even during periods of broader market weakness.
The risk-adjusted return metrics are particularly damaging. With a one-year absolute return of -49.75% and volatility of 44.35%, the stock's risk-adjusted return stands at -1.12, indicating investors have been punished with high volatility and negative returns—the worst possible combination. The stock's beta of 1.36 confirms it is significantly more volatile than the market, amplifying downside moves during corrections whilst failing to capture proportionate upside during rallies.
Compared to its sector, Shivalik Rasayan has underperformed by 55.91 percentage points over the past year, with the broader Pesticides & Agrochemicals sector returning 6.16%. This massive underperformance relative to industry peers suggests company-specific issues beyond sector-wide headwinds, likely related to the margin pressures and efficiency concerns highlighted in the financial analysis.
Investment Thesis: Value Trap or Turnaround Opportunity?
Shivalik Rasayan presents a classic investment dilemma: attractive valuation multiples colliding with fundamental quality concerns. The company's proprietary Mojo Score of 37 out of 100, resulting in a "SELL" rating, encapsulates the conflicting signals across different analytical dimensions. Understanding the interplay between these factors is crucial for making an informed investment decision.
The valuation dimension offers the strongest support for the stock, with the "Attractive" grade reflecting the P/E discount to industry peers and particularly the deep discount to book value. For contrarian investors, this could represent an entry point if the company can execute a profitability turnaround. However, the "Average" quality grade—driven by weak ROE of 6.12%, declining ROCE, and negative five-year EBIT growth—suggests the low valuation is justified rather than representing a bargain.
The "Flat" financial trend designation for Q4 FY26 captures the mixed nature of recent results: strong revenue growth offset by margin pressures and inconsistent profitability. The bearish technical trend, with the stock trading below most major moving averages and exhibiting high volatility, indicates continued selling pressure and lack of institutional support.
Key Strengths & Risk Factors
✅ Key Strengths
⚠️ Key Concerns
Outlook: What to Watch in Coming Quarters
📈 Positive Catalysts
🚩 Red Flags
The Verdict: Avoid – Quality Concerns Outweigh Valuation Appeal
Score: 37/100
For Fresh Investors: Avoid initiating positions. Whilst the P/BV of 0.69x appears attractive on the surface, the exceptionally weak ROE of 2.40%, declining ROCE of 3.89%, and negative five-year EBIT growth indicate fundamental quality issues that justify the valuation discount. The complete absence of mutual fund holdings and minimal institutional interest serve as red flags about business sustainability. The stock's 49.75% decline over the past year and bearish technical setup suggest further downside risk. Wait for sustained evidence of margin expansion and capital efficiency improvement over at least three consecutive quarters before considering entry.
For Existing Holders: Consider reducing positions or exiting on strength. The recent 14.04% surge on results day provides a tactical exit opportunity. Whilst Q4 FY26 showed strong revenue growth, the underlying profitability metrics remain deeply concerning. The flat financial trend designation, average quality grade, and bearish technical trend create an unfavourable risk-reward profile. Unless you have high conviction in management's ability to execute a dramatic operational turnaround, the prudent approach is to redeploy capital into higher-quality agrochemical companies with superior ROE profiles and institutional sponsorship. Set a mental stop-loss around ₹260-270 levels if choosing to hold.
Fair Value Estimate: ₹240-260 (18-26% downside from current price of ₹293.95). This estimate factors in the weak ROE of 6.12%, below-peer operating margins, and lack of institutional validation. The stock would become interesting only below ₹220, where the P/BV would approach 0.50x, creating sufficient margin of safety for deep value investors willing to accept high risk.
Note— ROCE = (EBIT - Other Income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. All investments carry risk, including the potential loss of principal.
